このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Comparison of the Effects of Kinesio Taping and Compression Bandaging on Edema, Range of Motion, Upper Extremity Function, and Grip Strength in Patients With Breast Cancer-Related Lymphedema

2026年11月10日 更新者:Halic University

This randomized crossover clinical trial aims to compare the effects of Kinesio Taping and compression bandaging on upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength in patients with breast cancer-related lymphedema.

A total of 44 participants will receive both treatment approaches in different sequences. Each intervention period will last 4 weeks, with a 2-week washout period between treatments. Manual lymphatic drainage will be applied three times per week during the intervention periods. Assessments will be performed at baseline, week 4, and week 10.

調査の概要

状態

招待による登録

詳細な説明

This randomized crossover clinical trial was designed to compare the effects of Kinesio Taping and compression bandaging on upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength in patients with breast cancer-related lymphedema.

A total of 44 participants will be randomly allocated to one of two treatment sequences. In the first 4-week treatment period, one group will receive Kinesio Taping combined with manual lymphatic drainage, while the other group will receive compression bandaging combined with manual lymphatic drainage. Manual lymphatic drainage will be administered three times per week during the intervention periods.

After completion of the first 4-week treatment period, a 2-week washout period will be implemented. Following the washout period, participants will cross over to the alternative intervention for an additional 4 weeks. Participants who initially received Kinesio Taping will subsequently receive compression bandaging, whereas participants who initially received compression bandaging will subsequently receive Kinesio Taping.

Clinical assessments will be performed at baseline, at the end of the first treatment period (week 4), and at the end of the second treatment period (week 10). Upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength will be evaluated at these time points.

The crossover design allows all participants to receive both therapeutic interventions and enables within-participant comparison of the effects of Kinesio Taping and compression bandaging. The 2-week washout period is included to reduce potential carryover effects from the first treatment period before initiation of the second intervention.

研究の種類

介入

入学 (推定)

44

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Bakırköy
      • Istanbul、Bakırköy、トルコ(Türkiye)、34149
        • Istanbul University Cerrahpaşa Faculty of Medicine Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  • Diagnosis of lymphedema following breast cancer treatment (confirmed by clinical evaluation or objective measurements).
  • Age between 18 and 75 years (adult participants will be included).
  • Willingness to participate voluntarily in the study and provision of written informed consent.
  • Unilateral lymphedema (to ensure standardization of assessments).
  • Lymphedema in the chronic stage (present for more than 3 months).
  • A stable condition in terms of lymphedema treatment (no other lymphedema treatment received within the last month).
  • Sufficient functional capacity to complete physical assessments and measurements (movement limitations should not be at a level that prevents evaluation).

Exclusion Criteria:

  • History of advanced-stage cancer or active metastatic disease.
  • Presence of severe cardiovascular or respiratory disease (e.g., heart failure, chronic obstructive pulmonary disease).
  • History of diabetic neuropathy or peripheral vascular disease (may affect lymphedema management due to circulatory impairment).
  • Presence of severe skin reactions or dermatological conditions (that compromise skin integrity and prevent tape application).
  • Pregnancy or breastfeeding.
  • History of allergic reactions to kinesio tape or compression bandages.
  • History of lymphatic drainage surgery or other surgical intervention within the past 6 months.
  • Diagnosis of bilateral lymphedema (only unilateral cases will be included to standardize the assessment process).
  • Inability to actively participate in the study due to mental or cognitive impairment.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Kinesiotaping Group

Patients with lymphedema who will receive kinesio taping treatment first, followed by compression bandaging.

MLD will accompany both groups throughout the intervention periods. MLD sessions will be administered by a trained physiotherapist three times per week for a total duration of 4 weeks in each treatment period.

Kinesio taping: This technique will be applied to the edematous extremity in accordance with lymphatic drainage directions, three times per week. The tapes will remain in place for 2-3 days at each application.

Compression bandaging: Multi-layer, short-stretch compression bandages will be reapplied after each MLD session (three times per week).

Due to the crossover design of the study, the applied interventions will be switched between groups after the initial 4-week treatment period. Prior to the second intervention phase, a 1-week washout period will be implemented to minimize potential carryover effects from the previous treatment. No treatment will be administered during this washout period.

実験的:Compression Bandaging

Patients with lymphedema who will receive compression bandaging first, followed by kinesio taping treatment.

MLD will accompany both groups throughout the intervention periods. MLD sessions will be administered by a trained physiotherapist three times per week for a total duration of 4 weeks in each treatment period.

Kinesio taping: This technique will be applied to the edematous extremity in accordance with lymphatic drainage directions, three times per week. The tapes will remain in place for 2-3 days at each application.

Compression bandaging: Multi-layer, short-stretch compression bandages will be reapplied after each MLD session (three times per week).

Due to the crossover design of the study, the applied interventions will be switched between groups after the initial 4-week treatment period. Prior to the second intervention phase, a 1-week washout period will be implemented to minimize potential carryover effects from the previous treatment. No treatment will be administered during this washout period.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Upper Extremity Edema
時間枠:The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Arm circumference measurement was used as an objective indicator of lymphedema severity. Circumferential measurements were obtained using a non-elastic tape measure at standardized anatomical landmarks along the upper extremity. Measurements were taken at fixed intervals (e.g., every 5 cm) starting from the wrist and progressing proximally toward the elbow and upper arm.

Values were recorded in millimeters (mm), with higher circumference values indicating greater edema severity. There is no predefined upper limit for arm circumference; therefore, larger measurements reflect increased fluid accumulation, whereas smaller values indicate reduced edema.

To quantify lymphedema, the difference in circumference between the affected and unaffected extremities was calculated at each measurement point. A greater inter-limb difference represents more severe lymphedema, while a reduction in this difference over time indicates clinical improvement.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Pain Intensity
時間枠:The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

The Visual Analog Scale (VAS) is a 10-centimeter horizontal line used to assess pain intensity. Scores range from 0 to 10, where 0 indicates no pain and 10 indicates worst imaginable pain. Higher scores indicate greater pain severity.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Shoulder Range of Motion
時間枠:The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Joint range of motion (ROM) was assessed to evaluate upper-extremity mobility in individuals with lymphedema. Active ROM measurements were obtained using a standard universal goniometer based on anatomical landmarks. Measurements were recorded in degrees (°) for wrist, elbow, forearm, and shoulder movements.

Higher ROM values indicate greater joint mobility and better functional status, whereas lower values reflect movement limitation. As ROM does not have a single fixed maximum value, results were interpreted relative to anatomical normative values and the contralateral limb.

A reduction of ≥10° compared with the unaffected side was considered a clinically meaningful limitation, while an increase toward normal values over time was interpreted as a positive treatment response. Each movement was measured three times, and the mean value was used for analysis. ROM assessments were performed at baseline and after each intervention period.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Upper Extremity Function
時間枠:The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Upper-extremity functioning was assessed using the Disabilities of the Arm, Shoulder and Hand (QuickDASH) Functioning Scale, a self-reported questionnaire designed to evaluate physical function and symptoms related to upper-limb disorders. The QuickDASH consists of 30 items, each scored on a 5-point Likert scale ranging from 1 (no difficulty) to 5 (unable to perform or extreme difficulty).

Item scores are combined and transformed into a total score ranging from 0 to 100, where 0 indicates no disability and 100 represents the most severe functional limitation. Higher scores therefore reflect worse upper-extremity functioning and greater disability.

A decrease in QuickDASH score over time indicates functional improvement, whereas an increase reflects worsening functional status. The QuickDASH has no absolute clinical cut-off; however, changes of 10-15 points are generally considered clinically meaningful.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Grip Strength
時間枠:The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Grip strength was assessed using a Jamar hand dynamometer, a widely accepted and reliable instrument for measuring isometric hand grip strength in clinical and research settings. Measurements were recorded in kilograms (kg), with higher values indicating greater muscle strength and better functional capacity, and lower values reflecting reduced grip strength.

Participants were seated in a standardized position with the shoulder adducted and neutrally rotated, the elbow flexed at 90 degrees, the forearm in a neutral position, and the wrist positioned between 0-30° extension and 0-15° ulnar deviation. Participants were instructed to squeeze the dynamometer with maximal effort for a few seconds. Each hand was tested three times, with adequate rest between trials to minimize fatigue, and the mean value was used for analysis.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Seda Yildiz, PhD、Halic University

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年2月8日

一次修了 (推定)

2027年1月1日

研究の完了 (推定)

2027年4月1日

試験登録日

最初に提出

2026年2月23日

QC基準を満たした最初の提出物

2026年11月2日

最初の投稿 (実際)

2026年11月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年2月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All data obtained from the assessment scales used in the study will be shared; however, patients' personal information, including names, surnames, and contact details, will be kept confidential. These personal data will only be shared on an individual basis if specifically requested.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • ICF
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する